



Cost Recovery

Thomas J. Montine, MD, PhD
Alvord Professor and Chair
Department of Pathology
University of Washington

Cost Recovery by ADC Neuropath Cores

- + Web survey of all current ADC Neuropath Cores
 - + Included NIA policy on cost recovery
 - + Several questions about cost recovery
- + Results
 - + About 50% of ADC Neuropath Cores responded (14 Centers)

Results (con't)

- + "Does your core have a cost recovery program?"
 - + "No" in 11 of 14 Centers except for shipping
 - + "Yes" in 3 of 14 Centers
 - + Whether "Yes" or "No" several commented that they would appreciate more specific guidelines

3 of 14 Cores with Cost Recovery

+ Institution #1

- + Calculate materials and staff time from detailed fee schedule (annual update)
- + Does not include effort to diagnose or initial banking because thinks these activities already are paid for by ADC award
- + Priority: within institution, other ADC's, other academic or research institutions, industry (rare)

3 of 14 Cores with Cost Recovery

+ Institution #2

+ Tiered: Yes

+ ≤ 10 samples = no charge

+ > 10 then calculate materials and staff time to select, pull, and distribute (annual update)

+ Priority: NIH-funded, other funded, preliminary studies for grant applications, other

3 of 14 Cores with Cost Recovery

+ Institution #3

- + Cost of running Core minus funding to calculate “specimen price” ranging from \$100 \$200 to academic centers.
- + Tiered
 - + Tissue for pilot studies at no charge
 - + Charges to industry are several times higher

Summary and Recommendations

+ Summary

- + 14 ADC NP Cores responded
 - + About 80% without cost recovery beyond shipping costs
 - + About 20% with cost recovery programs
 - + Each is different in what is eligible for recovery, fees, tier of charges, and priority

+ Recommendation

- + NACC Neuropathology Committee appoint a subcommittee to establish more specific cost recovery guidelines and report back by 2013 meeting.